z-logo
Premium
Identifying factors affecting the pharmacokinetics of voriconazole in patients with liver dysfunction: A population pharmacokinetic approach
Author(s) -
Tang Dan,
Song BaiLi,
Yan Miao,
Zou JianJun,
Zhang Min,
Zhou HuaYing,
Wang Feng,
Xiao YiWen,
Xu Ping,
Zhang BiKui,
Chen XiJing,
Xiang DaXiong,
Linh Banh Hoan
Publication year - 2019
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/bcpt.13208
Subject(s) - voriconazole , pharmacokinetics , medicine , pharmacology , cyp2c19 , bioavailability , population , volume of distribution , antifungal , cytochrome p450 , dermatology , environmental health , metabolism
Voriconazole is a broad‐spectrum antifungal agent commonly used to treat invasive fungal infections. Voriconazole has significant intraindividual and interindividual pharmacokinetics variability in different patient populations. Pharmacokinetic data of voriconazole in patients with liver dysfunction were limited. The aims of this study were to evaluate the population pharmacokinetics of voriconazole in patients with liver dysfunction and to identify the factors that affect voriconazole pharmacokinetics. A total of 166 samples taken from 57 patients with liver dysfunction were included in the study. A one‐compartment pharmacokinetic model with first‐order absorption and elimination was used to describe the data. Voriconazole clearance (CL) was 0.58 L/h, the volume of distribution ( V d ) was 134 L, and oral bioavailability ( F ) was 80.8%. This study showed that platelet count was significantly associated with voriconazole pharmacokinetic parameters. CYP2C19 polymorphisms had no effect on voriconazole pharmacokinetic parameters. Voriconazole CL was significantly decreased in patients with liver dysfunction. This study provides useful pharmacokinetics information for patients with liver dysfunction while highlighting the value of therapeutic drug monitoring in adjusting doses.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here